Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancerANNALS OF ONCOLOGYIF65.42023-08-010PRE
Design, power, and alpha levels in randomized phase II oncology trials随机II期肿瘤学试验中的设计，功率和alpha水平ESMO OPENIF8.32023-02-011OAAI
Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm?ESMO OPENIF8.32022-06-014OAAI
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? NoANNALS OF ONCOLOGYIF65.42020-09-0175OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向